cDC2s: new players in the tumor microenvironment and cancer immunotherapy

  • Laoui, Damya (Administrative Promotor)
  • Nana, Frank Aboubakar (Co-Promotor)

Project Details

Description

Dendritic cells (DCs) are crucial for the generation of antitumor immunity, but the current DC-based therapies only result in durable tumor regression in a small number of patients. Importantly, we demonstrated that cDC2s infiltrate mouse and human tumors and that cDC2-based vaccinations reached a significant antitumor response in mouse models of non-small lung carcinoma (NSCLC) that are resistant to the currently used immune checkpoint inhibitors (ICIs).

Therefore, this project aims to unravel the role of cDC2s in NSCLC in order to assess and enhance their potential as tumor vaccines. Hereto, we will characterize mouse and human tumor-cDC2s in depth using state-of-the-art technologies; unravel the functions of tumorcDC2 subpopulations; and provide a proof of concept for the use of tumorcDC2 in combination therapies for NSCLC. Therefore, the results of this project can serve as a basis for novel therapeutic approaches that improve objective and durable responses for NSCLC.
AcronymANI285
StatusActive
Effective start/end date1/03/2128/02/25

Flemish discipline codes

  • Immunology not elsewhere classified

Keywords

  • cDC2
  • tumor microenvironment
  • Cancer immunotherapy